Industry Insights: Bioconjugate momentum builds with wave of regulatory approvals, clinical advances, and conference data disclosures

Artios Pharma and GSK announced clinical collaboration to evaluate ATR inhibitor alnodesertib in combination with B7-H3-targeting ADC risvutatug rezetecan in gastrointestinal tumors [1]

Artios Pharma and GSK announced a clinical trial collaboration and supply agreement to evaluate alnodesertib, an ATR inhibitor, in combination with risvutatug rezetecan (Ris-Rez), GSK’s investigational B7-H3-targeting ADC with a Topo1 inhibitor payload, in patients with gastrointestinal tumors. GSK will sponsor and conduct the Phase 1 study and supply Ris-Rez, while Artios will supply alnodesertib and each party retains rights to its respective asset. The study is expected to open by the end of 2026.

Halozyme and GSK announced global collaboration to develop subcutaneous formulations of oncology therapeutics using drug delivery technology [2]

Halozyme Therapeutics announced a global collaboration and license agreement with GSK, under which GSK has licensed Halozyme’s ENHANZE^® drug delivery technology for subcutaneous administration of multiple oncology targets, including ADCs, with an option for additional future targets. The agreement marks Halozyme’s first collaboration applying ENHANZE to ADC subcutaneous delivery. ENHANZE is a recombinant human hyaluronidase-based technology designed to enable rapid, large-volume subcutaneous administration. Under the terms of the agreement, GSK will make an upfront payment and potential future milestone payments, with Halozyme entitled to royalties on net sales of products incorporating ENHANZE.

Waiv and Daiichi Sankyo announced collaboration to apply AI-powered computational pathology to biomarker discovery for an ADC program [3]

Waiv, a Paris-based AI precision testing company, announced a collaboration with Daiichi Sankyo to lead digital pathology biomarker discovery for an undisclosed ADC program. Under the agreement, Waiv will apply its computational pathology platform to early-phase clinical data, encompassing TME analysis across hematoxylin and eosin and immunohistochemistry-stained samples, biomarker discovery, and outcome prediction to identify biomarkers of treatment response ahead of subsequent clinical trial phases. The platform is designed for data-constrained settings, leveraging foundation models trained across hundreds of thousands of images from an international data network to extract predictive signals from whole slide images and identify novel histopathological biomarkers. The collaboration aims to support patient stratification and clinical decision-making for ADC development.

Gyre Therapeutics acquired Cullgen, adding degrader-antibody conjugate and targeted protein degrader pipeline assets; Collaborations, partnerships, and acquisitions. Credit: Gyre Therapeutics.

Gyre Therapeutics acquired Cullgen, adding degrader-antibody conjugate and targeted protein degrader pipeline assets [4]

Gyre Therapeutics announced the closing of its acquisition of Cullgen, a clinical-stage biopharmaceutical company focused on targeted protein degrader and degrader-antibody conjugate (DAC) therapies, in an all-stock transaction valued at approximately $300 million. Cullgen became a wholly owned subsidiary of Gyre, with Cullgen’s former chief executive officer Dr Ying Luo appointed President and Chief Executive Officer of the combined entity. The acquisition adds a preclinical and clinical pipeline of targeted protein degraders and DACs to Gyre’s existing portfolio.

Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services announced strategic collaboration to support ADC manufacturing [5]

Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services announced a strategic collaboration to support ADC development and manufacturing programs. Under the agreement, Piramal will refer customers seeking ADC manufacturing technology to Ajinomoto’s AJICAP™ platform, while Ajinomoto will refer customers to Piramal as a CDMO for manufacturing AJICAP-based products. A separate Material Transfer Agreement will facilitate technology transfer, equipping Piramal with the capabilities to manufacture AJICAP-based products. AJICAP is a site-specific conjugation and linker technology designed to produce ADCs with improved efficacy and reduced toxicity through streamlined processes. The collaboration aims to accelerate development timelines, simplify technology transfer, and support scale-up from early-stage development through commercial manufacturing.

Boehringer Ingelheim and Zai Lab announced clinical collaboration to evaluate dual DLL3-targeting combination in small cell lung cancer and neuroendocrine carcinomas [6]

Boehringer Ingelheim and Zai Lab announced a clinical collaboration to evaluate a dual DLL3-targeting combination strategy in extensive-stage small cell lung cancer (ES-SCLC) and poorly differentiated neuroendocrine carcinomas. The Phase 1b/2 study will assess the safety, tolerability, and preliminary clinical activity of obrixtamig, a bispecific DLL3/CD3 T-cell engager, combined with zocilurtatug pelitecan (zoci), a DLL3-targeting ADC comprising a humanized anti-DLL3 monoclonal antibody linked to a camptothecin derivative via the TMALIN® platform. Zai Lab will supply zoci, while Boehringer Ingelheim will sponsor and oversee clinical operations. Both agents have received US FDA Orphan Drug Designation and Fast Track Designation for SCLC.

Boehringer Ingelheim and Zai Lab announced clinical collaboration to evaluate dual DLL3-targeting combination in small cell lung cancer and neuroendocrine carcinomas; Collaborations, partnerships, and acquisitions. Credit: iStock.

Astellas submitted supplemental New Drug Application in Japan for perioperative enfortumab vedotin plus pembrolizumab in muscle-invasive bladder cancer [7]

Astellas announced the submission of a supplemental New Drug Application (sNDA) to Japan’s Ministry of Health, Labour and Welfare for perioperative PADCEV (enfortumab vedotin), a Nectin-4-targeting ADC, in combination with pembrolizumab, for adults with muscle-invasive bladder cancer eligible for cisplatin-containing chemotherapy. The submission is based on Phase 3 EV-304 trial data demonstrating a 47% reduction in risk of tumor recurrence, progression, or death and a 35% reduction in risk of death versus neoadjuvant gemcitabine and cisplatin chemotherapy. The safety profile was consistent with prior experience, with the most common treatment-related adverse events including pruritus, alopecia, diarrhea, and anemia.

Henlius received Australian regulatory body approval to initiate Phase 1 trial of cMET/EGFR bispecific ADC in advanced solid tumors [8]

Henlius announced that HLX48, a cMET/EGFR bispecific ADC developed using its proprietary Hanjugator™ platform, has received Human Research Ethics Committee (HREC) approval in Australia and been acknowledged by the Therapeutic Goods Administration (TGA), enabling a first-in-human Phase 1 trial in patients with advanced or metastatic solid tumors. HLX48 comprises a cMET/EGFR bispecific antibody conjugated to a camptothecin-based topoisomerase I (Topo1) inhibitor payload via a highly hydrophilic linker at a DAR of ~4, featuring an affinity-differentiated design that preferentially targets cMET to reduce EGFR-related normal tissue toxicity. Preclinical studies demonstrated bystander killing more than 10-fold stronger than deruxtecan and good tolerability in cynomolgus monkeys at 60 mg/kg administered once every 3 weeks.

Zai Lab received US FDA Fast Track Designation for DLL3-targeting ADC in extrapulmonary neuroendocrine carcinomas [9]

Zai Lab announced that the US FDA has granted Fast Track Designation to zoci for the treatment of extrapulmonary neuroendocrine carcinomas following progression after standard first-line therapy. This is the second Fast Track Designation for zoci, following a designation for extensive-stage SCLC in May 2025. Preliminary data from an ongoing Phase 1b/2 registration-enabling study reported an objective response rate of 38.2% in heavily pretreated patients with extrapulmonary neuroendocrine carcinomas, with a manageable safety profile.

ArriVent BioPharma received US FDA IND clearance for a first-in-class tetravalent MUC16/NaPi2b-targeting ADC in ovarian and endometrial cancers [10]

ArriVent BioPharma announced US FDA IND clearance for ARR-002, a potential first-in-class tetravalent bispecific ADC co-targeting MUC16 and NaPi2b, with an initial focus in ovarian and endometrial cancers. The dual-target design is intended to enhance internalization, improve payload delivery, and address heterogeneous target expression. Preclinical data presented demonstrated simultaneous engagement of both targets, superior in vivo efficacy versus single-target ADCs in the OVCAR-3 xenograft model, and a favorable tolerability profile in cynomolgus monkeys at a higher maximum tolerated single dose versus comparator approaches. ArriVent expects to initiate a Phase 1 trial and dose the first patient in the second half of 2026.

InnoCare Pharma received IND approval in China for CDH17-targeting ADC in gastrointestinal cancers [11]

InnoCare Pharma announced that China’s Center for Drug Evaluation has approved the IND application for ICP-B208, a novel CDH17-targeting ADC comprising a humanized anti-CDH17 monoclonal antibody conjugated to a proprietary payload via a protease-cleavable linker, for the treatment of gastrointestinal cancers. CDH17 is a calcium-dependent cell adhesion protein with tumor-restricted expression implicated in tumor cell proliferation, migration, and metastasis. No approved CDH17-targeting ADCs currently exist. Preclinical studies demonstrated anti-tumor activity in CDH17-low tumors and improved cytotoxicity versus comparator agents.

Henlius received PMDA approval to conduct Phase 2/3 trial of PD-L1-targeting ADC HLX43 in squamous NSCLC in Japan [12]

Henlius announced that Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has permitted the HLX43-NSCLC302 study, an international, multicenter Phase 2/3 trial of HLX43, a PD-L1-targeting ADC with dual immune checkpoint blockade and cytotoxic payload mechanisms, in patients with advanced squamous NSCLC. The trial will be conducted across China, the US, and Japan, with the Phase 3 stage intended as the first pivotal registration study for HLX43 in this indication. Over 700 patients have been enrolled globally across HLX43 studies to date.

Taiho Oncology received US FDA IND clearance for CD79b-targeting ADC in non-Hodgkin lymphoma [13]

Taiho Oncology, Taiho Pharmaceutical, and Araris Biotech announced that the US FDA completed its IND review for ARC-02, enabling initiation of a Phase 1 dose-escalation trial in non-Hodgkin lymphoma. ARC-02 is a CD79b-targeting ADC with an MMAE payload, developed using Araris’ proprietary AraLinQ™ technology, which enables site-specific conjugation to the Q295 residue within the native antibody Fc framework via a hydrophilic isopeptide bond, without requiring custom antibody engineering. The approach is designed to preserve antibody pharmacokinetics and effector functions while enabling stable payload delivery.

Alphamab Oncology received IND acceptance for subcutaneous formulation of bispecific TROP2/HER3 ADC in China [14]

Alphamab Oncology announced that China’s Center for Drug Evaluation (CDE) has accepted the IND for JSKN016SC, a subcutaneous formulation of its bispecific TROP2/HER3-targeting ADC JSKN016, for the treatment of advanced solid tumors. JSKN016 is site-specifically conjugated via glycosylation to a Topo1 inhibitor payload at a DAR of 4. The Phase 1b dose-escalation and expansion study will evaluate safety, tolerability, pharmacokinetics, and anti-tumor activity in Chinese patients. Compared with intravenous formulations, the subcutaneous formulation aims to reduce administration time and improve patient convenience and compliance.

US FDA accepted supplemental BLA for PADCEV plus pembrolizumab in muscle-invasive bladder cancer regardless of cisplatin eligibility; Regulatory changes and updates. Credit: PADCEV.

US FDA accepted supplemental BLA for PADCEV plus pembrolizumab in muscle-invasive bladder cancer regardless of cisplatin eligibility [15]

Astellas and Pfizer announced that the US FDA accepted a supplemental BLA (sBLA) for perioperative PADCEV, in combination with pembrolizumab, for patients with muscle-invasive bladder cancer (MIBC), regardless of cisplatin eligibility, for priority review. The filing seeks to expand a November 2025 approval, which was limited to cisplatin-ineligible patients. The sBLA is supported by Phase 3 EV-304 trial data demonstrating a 47% reduction in risk of recurrence, progression, or death, a 35% reduction in risk of death, and a pathological complete response rate of 55.8% versus 32.5% for neoadjuvant gemcitabine and cisplatin.

GSK received approval for Blenrep in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma in China [16]

GSK announced that China’s National Medical Products Administration (NMPA) has approved Blenrep (belantamab mafodotin) in combination with bortezomib and dexamethasone for adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy. The approval, supported by priority review and Breakthrough Therapy Designation, is based on data from the pivotal Phase 3 DREAMM-7 trial, which demonstrated statistically significant improvements in progression-free survival and overall survival versus daratumumab, bortezomib, and dexamethasone. Belantamab mafodotin is a BCMA-targeting ADC and the only anti-BCMA ADC approved in multiple myeloma.

NICE recommended Blenrep in combination with bortezomib and dexamethasone for relapsed multiple myeloma on the NHS [17]

The National Institute for Health and Care Excellence (NICE) issued final draft guidance recommending Blenrep in combination with bortezomib and dexamethasone, for adults with relapsed multiple myeloma following one prior line of therapy on the NHS in England. The recommendation broadens previous draft guidance, which had been restricted to patients whose prior treatment included lenalidomide. Clinical evidence demonstrated extended progression-free survival versus daratumumab, bortezomib, and dexamethasone, with early data suggesting a potential overall survival benefit. Interim funding will be made available immediately through the Cancer Drugs Fund, with approximately 1,600 patients per year in England expected to benefit.

Daiichi Sankyo announced JPY 75.7 billion in CMO compensation fees and manufacturing impairment charges following downward revision of ADC business demand forecasts [18]

Daiichi Sankyo announced it will pay compensation totaling JPY 75.7 billion ($483 million) to CMOs following a reduction in its ADC business demand forecast, alongside a JPY 19.3 billion impairment charge on its Odawara manufacturing plant. The charges stem from long-term contracts signed with CMOs based on earlier, higher demand estimates for its ADC portfolio, which includes Enhertu (trastuzumab deruxtecan) and datopotamab deruxtecan, co-developed with AstraZeneca, and patritumab deruxtecan, co-developed with Merck & Co. Revised demand forecasts were driven primarily by the postponed launch of patritumab deruxtecan and resulting reductions in target patient populations. Daiichi recorded an initial CMO compensation fee of JPY 12.7 billion and inventory valuation losses of JPY 4.6 billion in its second-quarter results.

Tacalyx secured €11 million in seed extension funding and selected first clinical candidate, a tumor-associated carbohydrate antigen-targeting ADC [19]

Tacalyx announced the selection of its first clinical candidate, TCX-201, an ADC targeting an undisclosed tumor-associated carbohydrate antigen (TACA) for gastrointestinal malignancies and other solid tumors, alongside a first closing of €11 million in seed extension funding from existing investors. The proceeds will support preclinical development of TCX-201 toward a clinical trial application filing in 2027, as well as advancement of the company’s broader pipeline.

Akari Therapeutics received Australian and European patent grants for proprietary Thailanstatin analog RNA splicing modulator payload for use in ADC therapeutics [20,21]

Akari Therapeutics announced the acceptance of an Australian patent and the grant of European Patent No. 3684773B1, providing broad composition-of-matter protection for its proprietary Thailanstatin-based RNA splice-modulating ADC payloads. The patents cover novel payload analogs designed for integration with advanced linker technologies and targeting across multiple tumor-associated antigens, underpinning the company’s proprietary PH1 payload platform. These grants expand an existing global intellectual property portfolio. The PH1 payload platform supports Akari’s ADC pipeline, including AKTX-101, a TROP2-targeting ADC currently in IND-enabling studies, and AKTX-102, targeting CEACAM5, with a first-in-human Phase 1 trial for AKTX-101 targeted for mid-2027.

Avacta presented comparative payload delivery analyses and updated in vivo dual-payload data [22]

Avacta presented new data at its Science Day 2026 event for two programs built on its FAP-activated pre|CISION® peptide-drug conjugate platform. For AVA6103, comparative pharmacokinetic analyses against two approved ADCs demonstrated more rapid tumor penetration, over 1-log higher tumor C_max, and a tumor selectivity index at least 3 times higher for released exatecan from AVA6103. For AVA6207, a dual-payload conjugate combining a Topo1 inhibitor and a DNA damage repair inhibitor, updated in vivo data demonstrated durable complete responses in a FAP-low/HER2-positive patient-derived gastric cancer model where Enhertu showed tumor regrowth, representing the first efficacy advantage demonstrated over a single-payload ADC in this model.

Binghamton University researcher received $2.75 million NIH grant to develop next-generation ADC technologies beyond oncology; Research and development highlights. Credit: Binghamton University.

Binghamton University researcher received $2.75 million NIH grant to develop next-generation ADC technologies beyond oncology [23]

L Nathan Tumey, associate professor at Binghamton University’s School of Pharmacy and Pharmaceutical Sciences, received a $2.75 million Maximizing Investigators’ Research Award (MIRA) from the National Institutes of Health (NIH) to develop next-generation ADC technologies for applications beyond oncology. Research focus areas include dual-payload ADCs combining immune agonists with cytotoxins to reprogram tumor-associated immune cells, targeted delivery of immunosuppressive agents to cells implicated in autoimmune diseases such as rheumatoid arthritis and lupus, and a novel class of organometallic catalyst payloads designed to deliver catalytic functions to targeted cells rather than simply inhibiting biological pathways. The flexible MIRA funding mechanism supports broad technology development without predefined specific aims.

Phase 2 trial reported encouraging clinical activity for sacituzumab govitecan in recurrent uterine cancer [24]

A Phase 2 trial reported encouraging activity for sacituzumab govitecan (SG), a TROP2-targeting ADC, in patients with recurrent endometrial cancer who had received 1–4 prior lines of therapy. Among evaluable patients, 28% experienced tumor reduction or disappearance at a median follow-up of 11 months, including a 4% complete response rate and 24% partial response rate, with a median response duration of 9.3 months. Median progression-free survival and overall survival were 5.5 months and 17.5 months, respectively. Activity was observed across histological subtypes including endometrioid tumors, uterine serous carcinoma, and carcinosarcoma. No new safety concerns were identified, with manageable side effects including fatigue and nausea.

NextCure and Simcere Zaiming initiated dose optimization portion of Phase 1 study of CDH6-targeting ADC SIM0505 in platinum-resistant ovarian cancer [25]

NextCure and Simcere Zaiming announced initiation of the dose optimization portion of the Phase 1 study of SIM0505, a CDH6-targeting ADC with a proprietary Topo1 inhibitor payload, focusing on patients with platinum-resistant ovarian cancer. The dose optimization phase is designed to finalize dose selection and support advancement toward registrational studies. The program is being accelerated through expansion of clinical sites across the US, China, Canada, and Europe. SIM0505 has received US FDA Fast Track Designation for platinum-resistant ovarian cancer. Phase 1 data are expected to be presented at ASCO 2026. NextCure holds exclusive global rights for SIM0505 outside of China, Hong Kong, Macau, and Taiwan, which are retained by Simcere Zaiming.

Telix reported progress on a PSMA-targeting radio-ADC in the Phase 3 ProstACT Global trial in metastatic castration-resistant prostate cancer [26]

Telix provided an update on its prostate cancer therapeutic pipeline, including TLX591-Tx (lutetium-177 rosopatamab tetraxetan), a PSMA-targeting radio-ADC (rADC) currently being evaluated in the Phase 3 ProstACT Global trial in metastatic castration-resistant prostate cancer. The study is actively dosing patients in jurisdictions with regulatory approval and has recently reported safety and dosimetry lead-in data.

Mabwell initiated Phase 3 study of Nectin-4-targeting ADC in triple-negative breast cancer; Clinical trials and research. Credit: iStock.

Mabwell initiated Phase 3 study of Nectin-4-targeting ADC in triple-negative breast cancer [27]

Mabwell announced the initiation of a Phase 3 clinical study of 9MW2821, a Nectin-4-targeting ADC, in patients with locally advanced or metastatic triple-negative breast cancer (TNBC) who have previously received taxane-based chemotherapy and a topoisomerase inhibitor-based ADC. The randomized, open-label, controlled, multicenter study will evaluate 9MW2821 versus investigator’s choice chemotherapy. This represents the fourth pivotal trial initiated for 9MW2821, which has previously entered Phase 3 studies in urothelial carcinoma and cervical cancer. 9MW2821 has received US FDA Fast Track Designation for locally advanced or metastatic Nectin-4-positive TNBC.

ASCO expanded TAPUR study to include Enhertu as its first ADC cohort [28]

The American Society of Clinical Oncology (ASCO) expanded its Targeted Agent and Profiling Utilization Registry (TAPUR™) study to include Enhertu, marking the first ADC to be incorporated into the platform. The study will evaluate the ADC in solid tumors with HER2 gene amplification and in non-SCLC (NSCLC) with HER2 IHC2+/3+, building on the US FDA accelerated approval granted in April 2024 for HER2-positive unresectable or metastatic solid tumors. The TAPUR study evaluates off-label use of targeted therapies using genomic profiling, with participating patients receiving treatment at no cost. The study has enrolled more than 3,000 patients across 272 sites in the USA.

Piramal Pharma Solutions launched new payload-linker development and manufacturing suite at its Riverview, Michigan facility [29]

Piramal Pharma Solutions unveiled a new payload-linker development and manufacturing suite at its drug substance facility in Riverview, Michigan, as part of a broader $90 million investment plan to expand US-based manufacturing capabilities. The suite is equipped with advanced containment, automation, and analytical technologies to support seamless scaling of payload-linker programs and strengthens Piramal’s ADCelerate™ platform, its integrated approach to Phase 1 ADC development. Riverview serves as Piramal’s dedicated payload-linker supplier, leveraging the site’s existing highly potent active pharmaceutical ingredient expertise. The additions are designed to support rising demand for ADCs and other bioconjugate therapies.

Ring Therapeutics presented data on Vector Oligonucleotide Conjugate platform and VectorBricks™ manufacturing technology at ASGCT 2026 [30]

Ring Therapeutics presented data at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2026 on two innovations in targeted oligonucleotide delivery. A poster introduced Vector Oligonucleotide Conjugates (VOCs), a modular platform combining recombinant viral capsids with directly conjugated synthetic siRNA, with controllable surface decoration with targeting ligands including small molecules and monoclonal antibodies, demonstrating target gene knockdown in vitro with enhanced potency in targeted versus untargeted VOCs. An oral presentation outlined VectorBricks™, a modular in vitro capsid assembly manufacturing platform using recombinant Anellovirus capsid proteins capable of packaging diverse payloads including small molecules, siRNA, and DNA, demonstrated at 50-liter scale with cell-specific productivity comparable to monoclonal antibody manufacturing processes.

Pheast Therapeutics presented first preclinical data for CDH1/Nectin-4 bispecific ADC at PEGS Boston Summit 2026 [31]

Pheast Therapeutics presented first preclinical data for PHST677, a bispecific ADC co-targeting CDH1 (E-cadherin) and Nectin-4, at the PEGS Boston Summit 2026. CDH1 was identified via Pheast’s functional genomic screening platform as a novel negative regulator of macrophage phagocytosis, with significant upregulation across multiple solid tumor types. PHST677 is designed to combine CDH1-mediated macrophage activation with Nectin-4-directed cytotoxic payload delivery, restricting internalization to cells co-expressing both targets to improve tumor selectivity and reduce on-target, off-tumor toxicity. Preclinical studies demonstrated selective internalization and efficacy in breast and bladder cancer xenograft models.

Kodiak Sciences presented preclinical data on its antibody biopolymer conjugate platform for high drug-to-antibody ratio ocular drug delivery at ARVO 2026 [32]

Kodiak Sciences presented preclinical data at the Association for Research in Vision and Ophthalmology (ARVO) 2026 on its Antibody Biopolymer Conjugate Drug (ABCD™) platform, designed to overcome the DAR limitations of conventional ADCs and AOCs by leveraging a customizable biopolymer scaffold. One poster demonstrated receptor-mediated internalization and endosomal trafficking of antibody biopolymer conjugates in primary endothelial cells using an anti-VEGFR2 model, supporting the platform’s potential for intracellular payload delivery in retinal diseases. A second poster presented a dual-payload glaucoma conjugate incorporating an NLRP3 inflammasome inhibitor and an intraocular pressure-lowering agent, featuring pH-labile linkers that enable controlled sequential payload release, highlighting the platform’s versatility across ophthalmic indications.

Coave Therapeutics presented preclinical data on ligand-conjugated AAV vectors at ARVO 2026 [33]

Coave Therapeutics presented preclinical data at ARVO on its ligand-conjugated suprachoroidal vector platform. Presentations covered coAAV-SCS, a first-in-class ligand-conjugated AAV vector engineered using the company’s ALIGATER™ technology, demonstrating posterior segment targeting across multiple non-human primate studies. Data were also presented for CoTx-101, the company’s lead ophthalmology program, a dual-pathway AAV gene therapy for wet age-related macular degeneration and other retinal vascular diseases delivered via coAAV-SCS. The presentations highlight the potential of ligand-conjugated vector technology to improve targeted delivery to ocular tissues via the suprachoroidal route.

Decoy Therapeutics presented preclinical data on peptide conjugate antiviral therapeutics at peptide therapeutics conferences in Boston [34]

Decoy Therapeutics presented across two peptide therapeutics conferences in Boston in April 2026. At the 3rd Annual Peptide-Based Therapeutics Summit, the company presented new preclinical data for its Designable Multi-Antiviral (D-MAV™) programs, built on its proprietary IMP3ACT™ peptide conjugate platform, which integrates AI-enabled peptide design with rapid synthesis and manufacturing. The presentation examined how peptide conjugates enable design-led development of therapeutics targeting shared viral mechanisms, moving beyond conventional single-virus approaches. Lead programs include a preclinical pan-coronavirus fusion inhibitor and a discovery-stage broad antiviral targeting influenza, COVID-19, and respiratory syncytial virus. At the Oligonucleotide & Peptides HubXchange, the company discussed computational approaches to de novo peptide design, including a strategic partnership with Quantori to deploy an AI-driven peptide design platform.

Dyne Therapeutics presented preclinical data on TfR1-targeting antibody-siRNA conjugates for CNS delivery at ASGCT 2026 [35]

Dyne Therapeutics presented preclinical data at ASGCT demonstrating CNS delivery and MAPT RNA knockdown using two TfR1-targeting antibody fragment (Fab)-siRNA conjugates. Both conjugates, built on the company’s FORCE platform, achieved approximately 75% MAPT RNA knockdown across brain regions, including deep brain structures, in mice and non-human primates. Conjugate 1 utilizes the clinically validated FORCE Fab used in Dyne’s Duchenne muscular dystrophy and myotonic dystrophy type 1 programs, while Conjugate 2 incorporates a modified Fab optimized for enhanced CNS delivery. Subcutaneous administration achieved equivalent knockdown to intravenous dosing in mice.

Company updates and presentations from the AACR Annual Meeting 2026 covering advances in ADC and bioconjugate platforms; Conferences, events, and publications. Credit: AACR.

Company updates and presentations from the AACR Annual Meeting 2026 covering advances in ADC and bioconjugate platforms [36–61]

Several companies presented data at the American Association for Cancer Research (AACR) Annual Meeting 2026 (April 17–22, San Diego, CA, USA). Companies and their topics include:

• Actinium Pharmaceuticals: Preclinical data for ATNM-400, a first-in-class Actinium-225 radioconjugate targeting a non-PSMA membrane antigen overexpressed in treatment-refractory solid tumors, demonstrating anti-tumor activity across prostate cancer, EGFR-mutant NSCLC, and trastuzumab-resistant HER2+ breast cancer, with superiority over 177Lu-PSMA-617 in prostate models and comparable efficacy to Enhertu in breast cancer models.
• Adcendo: Preclinical data for ADCE-T02, a tissue factor-targeting ADC with a Topo1 inhibitor payload, demonstrating efficacy in head and neck squamous cell carcinoma (HNSCC) preclinical models, alongside publication of additional preclinical data showing no evidence of ocular, skin, lung, peripheral nerve, or bleeding toxicity in non-human primates.
• Akari Therapeutics: Preclinical data for AKTX-101 demonstrating sub-nanomolar potency across bladder, lung, and breast cancer cell lines and superior cytotoxicity versus TROP2 ADCs with Topo1 inhibitor payloads, including in HER2 breast cancer lines with inherent resistance to Enhertu.
• Angiex: Preclinical in vivo data for AGX101, a TM4SF1-directed tubulin inhibitor ADC targeting the tumor vasculature, in combination with immune checkpoint inhibitors targeting PD-1 or CTLA-4, across solid tumor models.
• Antengene: Preclinical data for ATG-125, a bispecific B7-H3 x PD-L1 ADC designed to combine direct tumor cell killing via payload delivery with immune checkpoint blockade, demonstrating antitumor activity in xenograft and syngeneic models alongside enhanced intratumoral CD8+ T-cell infiltration.
• Avacta Therapeutics: Preclinical and Phase 1 trial-in-progress data for AVA6103, a FAP-activated peptide-drug conjugate delivering exatecan to the tumor-stroma interface, demonstrating activity across patient-derived xenograft models with varying FAP expression and a tumor selectivity index three times higher than a comparator ADC. First in vivo data were also presented for AVA6207, a dual-payload FAP-activated conjugate combining a Topo1 inhibitor and a DNA damage repair inhibitor, showing synergistic tumor cell killing in Topo1 inhibitor-resistant models.
• BeyondSpring: Preclinical data for plinabulin, a dendritic cell maturation agent, in combination with Enhertu and datopotamab deruxtecan, demonstrating increased tumor regression rates, improved survival, and enhanced CD8+ T cell/Treg ratio versus ADC monotherapy, alongside reduced treatment-related neutropenia in two- and three-drug combinations including a PD-1 inhibitor.
• Bicycle Therapeutics: Phase 1/2 data for nuzefatide pevedotin, an EphA2-targeting Bicycle® Drug Conjugate, reporting a 40% confirmed overall response rate in EphA2+ metastatic urothelial cancer patients in combination with nivolumab, alongside preclinical anti-tumor activity in patient-derived xenograft models of pancreatic ductal adenocarcinoma and HNSCC, and human PET/CT imaging data validating EphA2 expression in pancreatic ductal adenocarcinoma.
• Biolojic Design: Preclinical data for BD200, a first-in-class multibody-drug conjugate targeting both Trop-2 and Nectin-4, demonstrating antitumor activity across multiple solid tumor models, including in ADC-resistant settings, with clinical trials expected to initiate in the second half of 2026.
• Byondis: Preclinical data for two novel ADC platforms: a first-in-class antifolate linker-drug platform demonstrating tumor regressions in NSCLC and HNSCC patient-derived xenograft models, and ByonBoost™, a phosphonate linker-drug platform designed to activate Vγ9Vδ2 γδ T cells in the TME, with broad applicability across targets including CD123, CD20, TROP2, and HER2.
• Crown Bioscience: Integrated patient-derived platforms for ADC and radiopharmaceutical development, including a high-throughput organoid platform for payload screening, ADC-resistant tumor models, and multiomics target validation across approximately 1,000 patient-derived xenograft models.
• CStone Pharmaceuticals: Preclinical data for three ADCs built on its proprietary CSL20 linker-exatecan platform: CS5007 (bispecific EGFR/HER3-targeting), CS5006 (ITGB4-targeting), and CS5008 (bispecific DLL3/SSTR2-targeting, DAR4), with CS5008 designed to address intra- and inter-tumoral heterogeneity in SCLC and neuroendocrine tumors through dual targeting of two antigens overexpressed across these indications.
• Dana-Farber Cancer Institute: Phase 1 data for the combination of Enhertu and olaparib in 28 patients with HER2-expressing advanced solid tumors, reporting a confirmed objective response rate of 46%, median progression-free survival of 15.2 months, and identification of an intermittent olaparib dosing schedule as the recommended dose for expansion.
• NEOK Bio: Preclinical data for two bispecific ADCs: NEOK001 (targeting B7-H3 and ROR1) demonstrating 84% tumor growth inhibition across 38 patient-derived xenograft models, and NEOK002 (targeting EGFR and MUC1) achieving tumor regression in 78% of 36 patient-derived xenograft models. Both utilize a DAR 4 Topo1 inhibitor payload and received US FDA IND approval in Q1 2026.
• OncoNano Medicine: Preclinical data for its ON-BOARD™ platform, an ultra pH-sensitive polymer-drug conjugate technology enabling antigen-independent, TME-activated payload delivery, including data for ONM-421, an MMAE-bearing polymer-drug conjugate demonstrating broader activity than an MMAE-based ADC in low-antigen-expressing tumor models.
• Orum Therapeutics: Preclinical data for ORM-1153, a CD123-targeting DAC delivering a proprietary GSPT1-degrading payload, demonstrating anti-leukemia activity across primary acute myeloid leukemia patient samples, including TP53-mutant models, with favorable tolerability in non-human primates, ahead of a planned regulatory submission in the second half of 2026.
• Pyxis Oncology: Preclinical data for MICVO (micvotabart pelidotin), an ADC targeting extradomain-B of fibronectin in the tumor extracellular matrix, demonstrating dose-dependent tumor growth inhibition and synergistic anti-tumor activity in combination with anti-PD-1 in an immunotherapy-refractory syngeneic HNSCC model, with modulation of the TME toward a more immune-permissive state.
• Qilu Pharmaceutical: Phase 1 clinical data for QLS5132, a CLDN6-targeting ADC with a Topo1 inhibitor payload at a DAR ratio of 8:1, reporting a 50% objective response rate and 94.4% disease control rate across all dose levels in 18 evaluable patients with platinum-resistant ovarian cancer, with responses observed irrespective of CLDN6 expression levels.
• Salubris Biotherapeutics: Phase 1/2 expansion cohort data for JK06, a first-in-class biparatopic 5T4-targeting ADC with an MMAE payload, reporting an overall response rate of 26% in both NSCLC and breast cancer patients, with a favorable safety profile across 112 patients.
• Samsung Bioepis: Nonclinical characterization of SBE303, a Nectin-4-targeting ADC conjugated with a novel Topo1 inhibitor via a proprietary linker, demonstrating robust antitumor activity with no interstitial lung disease findings at doses ≥40 mg/kg; SBE303 is currently in Phase 1 clinical development.
• Shanghai Henlius Biotech: First disclosure of preclinical data for multiple ADC candidates derived from its proprietary Hanjugator™ camptothecin-based linker-payload platform, including HLX48 (cMET/EGFR bispecific ADC), HLX49 (HER2 biparatopic ADC), HLX402 (ADAM9-targeting ADC designed to mitigate ocular toxicity), and HLX85 (ALPP/ALPPL2-targeting ADC), with all candidates showing favorable tolerability in non-human primates.
• Sutro Biopharma: Preclinical data across ADC pipeline, including STRO-004 (tissue factor-targeting, DAR8 exatecan) demonstrating robust antitumor activity across patient-derived xenograft models; STRO-006 (integrin β6-targeting, DAR8 exatecan) in NSCLC and HNSCC; and STRO-227 (PTK7-targeting dual-payload ADC, DAR10; 8 exatecan + 2 MMAE) showing improved efficacy versus single-payload ADCs.
• Synthetic Design Lab: First public preclinical data for its SYNTHBODY™ platform, a logic-gated multi-protein binding architecture combining affinity-tuned binders for BCMA, GPRC5D, and CD38, demonstrating more than 80× greater potency versus belantamab mafodotin in human myeloma cells and more than 30× greater internalization versus belantamab when bioconjugated to MMAF, with early data also presented for a non-Hodgkin’s lymphoma-targeting construct.
• Whitehawk Therapeutics: Preclinical data for three ADCs built on its Carbon Bridge Cysteine Re-pairing platform: HWK-007 (PTK7-targeting), HWK-016 (MUC16-targeting), and HWK-206 (biparatopic SEZ6-targeting), each demonstrating tumor regressions at doses as low as 1–2 mg/kg, high plasma stability (free payload ≤0.01% AUC), and favorable tolerability in non-human primates (HNSTD 60 mg/kg).
• Zai Lab: Clinical data for zoci, a DLL3-targeting ADC, reporting a 53.7% confirmed intracranial objective response rate in ES-SCLC patients with brain metastases (62.5% at 1.6 mg/kg) and a 38.2% confirmed objective response rate in extrapulmonary neuroendocrine carcinomas. Preclinical data were also presented for ZL-6201, an LRRC15-targeting ADC for sarcoma and epithelial tumors.
• Zymeworks: Preclinical data on a novel pan-RAS inhibitor ADC platform (targeting PTK7, Ly6E, and CLDN18.2), a novel eIF4A inhibitor payload class, and Phase 1 clinical data from ZW191, a folate receptor alpha-targeting ADC, in advanced solid tumors.

Several companies announced presentations at ASCO 2026 [62–66]

Several companies announced poster and oral presentations at the ASCO Annual Meeting 2026 (May 30 to June 3, Chicago, IL, USA). Companies and their topics include:

• Bicycle Therapeutics: Interim Phase 2 data from the Duravelo-2 study for zelenectide pevedotin (BT8009), a Nectin-2-targeting Bicycle Drug Conjugate, as monotherapy in previously treated locally advanced/metastatic urothelial carcinoma and in combination with pembrolizumab in previously untreated locally advanced/metastatic urothelial carcinoma, alongside updated data from the Duravelo-1 and Duravelo-1 B7 studies.
• Corbus Pharmaceuticals: Updated Phase 1/2 data for CRB-701, a next-generation Nectin-4-targeting ADC with a site-specific cleavable linker, homogeneous DAR of 2, and MMAE payload, including clinical response durability and subgroup analyses in recurrent or metastatic HNSCC and cervical cancer.
• NextCure/Simcere Zaiming: Phase 1 first-in-human data for SIM0505, a CDH6-targeting ADC with a proprietary Topo1 inhibitor payload, in patients with advanced solid tumors including platinum-resistant ovarian cancer.
• Pfizer: Updated Phase 1 data for sigvotatug vedotin, an integrin β6-targeting ADC, in combination with pembrolizumab in NSCLC, supporting ongoing Phase 3 studies evaluating the ADC both in combination with pembrolizumab in first-line NSCLC and as monotherapy in previously treated advanced NSCLC.
• Tubulis: Phase 1 dose escalation data from the NAPISTAR 1-01 trial for TUB-040, a NaPi2b-targeting ADC with an exatecan payload, in patients with platinum-resistant ovarian cancer.

Lauren Coyle, Commissioning Editor, Bioconjugate Insights, has extensive experience in bioconjugation (i.e., ADCs, conjugate chemistry, diagnostics and imaging, bi/multi-specifics, targeted delivery, and theranostics). Lauren’s focus is on advancing the field by facilitating and disseminating high-impact research on bioconjugates, conjugation technologies, and their applications. Lauren works closely with researchers, scientists, and industry professionals to publish cutting-edge studies exploring the latest advances in conjugation chemistry, drug delivery systems, and the development and delivery of targeted therapeutics. In addition to her editorial responsibilities, she maintains a strong network within the biopharma industry, staying up to date with emerging trends and breakthroughs in bioconjugates.

References

1. Artios Pharma. Artios Announces Clinical Trial Collaboration with GSK to Evaluate Alnodesertib in Combination with Risvutatug Rezetecan, a B7-H3-Targeted ADC in Gastrointestinal Tumors. May 12, 2026.

2. Halozyme Therapeutics. Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets. May 7, 2026.

3. Waiv. Waiv Enters Collaboration with Daiichi Sankyo to Deliver AI-Derived Biomarkers for ADC Program. May 6, 2026.

4. Gyre Therapeutics. Gyre Therapeutics Completes Acquisition of Cullgen to Create US- and China-based Fully Integrated Biopharmaceutical Company. May 4, 2026.

5. Piramal Pharma. Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services Collaborate to Support ADC Development and Manufacturing. Apr 16, 2026.

6. Boehringer Ingelheim. Boehringer Ingelheim and Zai Lab announce collaboration on DLL3‑targeting T-Cell Engager and ADC combination in Small Cell Lung Cancer and other Neuroendocrine Carcinomas. Apr 15, 2026.

7. Astellas Pharma. Astellas Submits Supplemental New Drug Application in Japan for PADCEV™ (enfortumab vedotin) plus Keytruda® (pembrolizumab) in Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer. May 14, 2026.

8. Shanghai Henlius Biotech. Henlius’ c-Met/EGFR Bispecific ADC Approved for Clinical Trial in Australia. May 13, 2026.

9. Zai Lab. Zai Lab Receives US FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs). May 11, 2026.

10. ArriVent BioPharma. ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers. May 7, 2026.

11. InnoCare Pharma. InnoCare Pharma received IND approval in China for CDH17-targeting ADC ICP-B208 in gastrointestinal cancers. May 7, 2026.

12. Shanghai Henlius Biotech. Henlius’ HLX43 (anti-PD-L1 ADC) Receives PMDA’s Acknowledge to Initiate Global Phase 2/3 Trial in sqNSCLC. May 4, 2026.

13. Taiho Oncology. Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development. Apr 27, 2026.

14. Alphamab Oncology. Alphamab Oncology Announces IND Application for TROP2/HER3 Bispecific ADC JSKN016SC Officially Accepted by CDE. Apr 30, 2026.

15. Astellas Pharma. US FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility. Apr 20, 2026.

16. GSK. Blenrep (belantamab mafodotin) approved in China for treatment of 2L+ relapsed/refractory multiple myeloma. Apr 20, 2026.

17. National Institute for Health and Care Excellence. ‘Trojan horse’ treatment recommended for people with multiple myeloma. Apr 16, 2026.

18. Daiichi Sankyo. Daiichi Sankyo announced JPY 75.7B in CMO compensation fees and manufacturing impairment charges following downward revision of ADC business demand forecasts. May 8, 2026.

19. Tacalyx. Tacalyx Secures €11 Million to Advance Lead TACA-Targeting ADC Programme Toward the Clinic. Apr 29, 2026.

20. Akari Therapeutics. Akari Therapeutics Secures Australian Patent Approval, Further Expanding Global Protection of Its Proprietary PH1 RNA Splicing Modulator ADC Payload. Apr 27, 2026.

21. Akari Therapeutics. Akari Therapeutics Secures Key European Patent For Its Novel RNA Splicing Modulator ADC Payload, Strengthening Global IP Estate For All Major Global Markets. May 12, 2026.

22. Avacta Therapeutics. Avacta presents new comparisons of pre|CISION® payload release vs approved ADCs and AVA6207 dual payload delivery at Science Day 2026. May 6, 2026.

23. Binghamton University. Binghamton researcher awarded $2.75 million grant to develop next-gen cancer treatments. Apr 23, 2026.

24. Yale School of Medicine, Yale Cancer Center. Breast Cancer Drug Is Effective for Treatment-Resistant Uterine Cancer. May 14, 2026.

25. NextCure. NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers. May 4, 2026.

26. Telix Pharmaceuticals. OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer. Apr 30, 2026.

27. Mabwell. Mabwell Initiates Phase 3 Clinical Study of its Nectin-4-Targeting ADC 9MW2821 for the Treatment of Triple-Negative Breast Cancer. Apr 23, 2026.

28. ASCO. ASCO Expands Landmark Trial with First Antibody-Drug Conjugate Cohorts. Apr 17, 2026.

29. Piramal Pharma Solutions. Piramal Pharma Solutions Unveils State-of-the-Art Payload-Linker Suite at its Riverview, Michigan Facility. May 13, 2026.

30. Ring Therapeutics. Ring Therapeutics® Presents its Vector Conjugate and VectorBricks™ Manufacturing Platforms at the 29th Annual American Society of Gene & Cell Therapy Conference. May 14, 2026.

31. Pheast Therapeutics. Pheast Therapeutics Presents Preclinical Data on PHST677, a Novel Bispecific ADC Targeting CDH1 and Nectin-4 at PEGS Boston Summit 2026. May 11, 2026.

32. Kodiak Sciences. Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences. May 1, 2026.

33. Coave Therapeutics. Coave Therapeutics to present two posters at ARVO 2026, on first-in-class ligand-conjugated suprachoroidal vector and lead gene therapy program. Apr 22, 2026.

34. Decoy Therapeutics. Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston. Apr 27, 2026.

35. Dyne Therapeutics. Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting. Apr 27, 2026.

36. Actinium Pharmaceuticals. Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer Research Annual Meeting. Apr 22, 2026.

37. Adcendo. Adcendo ApS Provides Updates on Pipeline Progress and Recent Achievements for Its First- and Best-in-Class Antibody-Drug Conjugates. Apr 20, 2026.

38. Akari Therapeutics. Akari Therapeutics Reports Positive Preclinical Data for AKTX-101 Demonstrating Differentiated Cytotoxicity for First-in-Class TROP2 ADC Payload Targeting RNA Splicing. Apr 20, 2026.

39. Angiex. Angiex Reports AACR In Vivo Data Supporting AGX101 in Combination With Immune Checkpoint Inhibitors for Solid Tumors. Apr 17, 2026.

40. Antengene. Antengene Presents Three Novel Programs at AACR 2026, Highlighting Next-Generation ADC and AnTenGager® TCEs. Apr 18, 2026.

41. Avacta Therapeutics. Avacta data at AACR 2026 underline favorable profile of AVA6103 and advantages of pre|CISION® delivery platform. Apr 21, 2026.

42. BeyondSpring Pharmaceuticals. BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs. Apr 22, 2026.

43. Bicycle Therapeutics. Bicycle Therapeutics Provides Update on Nuzefatide Pevedotin and EphA2 Pipeline at the AACR Annual Meeting 2026. Apr 20, 2026.

44. Biolojic Design. Biolojic presented the first ever preclinical data on a multibody-drug conjugate, BD200, at the AACR 2026. Apr 19, 2026.

45. Byondis. Byondis to Present Data from its Novel ADC Technology Platforms at the American Society for Cancer Research Meeting 2026. Apr 17, 2026.

46. Crown Bioscience. Crown Bioscience Showcases Integrated Platforms Enabling Next-Generation Oncology Modalities, Including ADCs and Radiopharmaceuticals. Apr 16, 2026.

47. CStone Pharmaceuticals. CStone Presented Preclinical Data for CS5008 (SSTR2/DLL3 ADC) at AACR 2026. Apr 20, 2026.

48. Dana-Farber Cancer Institute. Dana-Farber Phase 1 Study Explores Toxicity Reduction in Combination of Trastuzumab Deruxtecan and Olaparib in Advanced HER2-Expressing Malignancies. Apr 19, 2026.

49. NEOK Bio. NEOK Bio Presentations at AACR 2026 Annual Meeting Showcase Potential of a Differentiated Bispecific Antibody Drug Conjugate Pipeline. Apr 17, 2026.

50. OncoNano Medicine. OncoNano to Present New Preclinical Data at AACR 2026 Highlighting Effective Tumor Delivery Enabled by ON-BOARD™ Platform. Apr 17, 2026.

51. Orum Therapeutics. Orum Presents New Preclinical Data at AACR 2026 on ORM-1153, a CD123-Targeting Degrader-Antibody Conjugate, Highlighting Broad Activity in AML and the Potential for Improved Efficacy and Tolerability. Apr 17, 2026.

52. Pyxis Oncology. Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026. Apr 17, 2026.

53. AACR. New Antibody-drug Conjugate Shows Clinical Benefit for Advanced Platinum-resistant Ovarian Cancer. Apr 19, 2026.

54. Salubris Biotherapeutics. Salubris Biotherapeutics Announces Expansion Cohort Data for JK06, 5T4-Targeted Antibody Drug Conjugate, at the American Association for Cancer Research Conference. Apr 17, 2026.

55. Samsung Bioepis. Samsung Bioepis Presents Nonclinical Data for its First Novel Antibody-Drug Conjugate Candidate SBE303 at AACR 2026. Apr 20, 2026.

56. Shanghai Henlius Biotech. Henlius Presents Four Hanjugator™ ADCs at AACR 2026, with Multiple Potential Best-in-Class Assets Advancing. Apr 23, 2026.

57. Sutro Biopharma. Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026. Apr 19, 2026.

58. Synthetic Design Lab. Synthbody™ A novel multivalent multispecific antibody drug conjugate platform demonstrates combinatorial logic-gated ‘synthetic’ targeting of cancer antigens with log order enhanced internalization and potency. Apr 18, 2026.

59. Whitehawk Therapeutics. Whitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AACR 2026. Apr 19, 2026.

60. Zai Lab. Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas. Apr 17, 2026.

61. Zymeworks. Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform. Apr 17, 2026.

62. Bicycle Therapeutics. Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting. Apr 21, 2026.

63. Corbus Pharmaceuticals. Corbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-701. Apr 22, 2026.

64. NextCure. NextCure and Simcere’s SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026. Apr 21, 2026.

65. Pfizer. Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026. Apr 21, 2026.

66. Tubulis. Tubulis to Present Phase I/IIa Trial Data for ADC Candidate TUB-040 in Platinum-resistant Ovarian Cancer in Rapid Oral Presentation at ASCO 2026. Apr 21, 2026.